Lessons and tactics to lead the charge against lead poisoning

Article

Nearly a half million children in the US are believed to have an elevated blood lead level. Pediatric health-care providers can intervene in a variety of ways. Includes a Guide for Parents.

Recent Videos
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Staphylococcus aureus risk in infants and neonatologist considerations with Aaron Milstone, MD
How fragrance plays a role in atopic dermatitis treatments, with John Browning, MD
Octavio Ramilo, MD, reacts to the FDA approval of clesrovimab for RSV prevention | Image Credit: St. Jude Children's Research Hospital
Related Content
FDA approves lenacapavir as PrEP for HIV in adults, adolescents weighing at least 35 kg | Image Credit: Contemporary Pediatrics

FDA approves twice-yearly lenacapavir as PrEP for HIV in adolescents, adults

Joshua Fitch, Senior Editor
June 18th 2025
Article

Lenacapavir is the first twice-yearly option available in the US for those who need or want PrEP, according to Gilead Sciences.

Site Logo

Food Insecurity and the Dangers of Infant Formula Dilution

January 30th 2023
Podcast
Phase 3 trial of omaveloxolone to treat Friedreich ataxia in children aged 2 to <16 begins | Image Credit: © 125154153 - stock.adobe.com.

Phase 3 trial of omaveloxolone to treat Friedreich ataxia in children aged 2 to <16 begins

Joshua Fitch, Senior Editor
June 18th 2025
Article

Currently, omaveloxolone (Skyclarys) is approved to treat adults and adolescents aged 16 years and older impacted by FA.

Demystifying Infant Formula

Demystifying Infant Formula

October 11th 2022
Podcast
FDA accepts NDA for epinephrine sublingual film to treat type 1 allergic reactions | Image credit: Contemporary Pediatrics

FDA accepts NDA for epinephrine sublingual film to treat type 1 allergic reactions

Joshua Fitch, Senior Editor
June 17th 2025
Article

The federal agency has assigned a target action date of January 31, 2026, for a decision.

FDA approves garadacimab-gxii to prevent HAE attacks in patients aged 12 years, older | Image credit: Contemporary Pediatrics

FDA approves garadacimab-gxii to prevent HAE attacks in patients aged 12 years, older

Joshua Fitch, Senior Editor
June 17th 2025
Article

Garadacimab-gxii is the only treatment to target factor Xlla for prophylactic use to prevent attacks of HAE in patients aged 12 years and older.

© 2025 MJH Life Sciences

All rights reserved.